Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 207

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma

Nault, Jean‐Charles, Martin, Yoann, Caruso, Stefano, Hirsch, Théo Z., Bayard, Quentin, Calderaro, Julien, Charpy, Cecile, Copie‐Bergman, Christiane, Ziol, Marianne, Bioulac‐Sage, Paulette, Couchy, Gabrielle, Blanc, Jean‐Frédéric, Nahon, Pierre, Amaddeo, Giuliana, Ganne‐Carrie, Nathalie, Morcrette, Guillaume, Chiche, Laurence, Duvoux, Christophe, Faivre, Sandrine, Laurent, Alexis, Imbeaud, Sandrine, Rebouissou, Sandra, Llovet, Josep M., Seror, Olivier, Letouzé, Eric, Zucman‐Rossi, Jessica · 2020 · Hepatology

Abstract

To date, genomic analyses of hepatocellular carcinoma (HCC) have been limited to early stages obtained from liver resection. We aim to describe the genomic profiling of HCC from early to advanced stages. We analyzed 801 HCC from 720 patients (410 resections, 137 transplantations, 122 percutaneous ablations, and 52 noncurative) for 190 gene expressions and for 31 gene mutations. Forty‐one advanced HCC and 156 whole exome of Barcelona Clinic Liver Cancer (BCLC) 0/A were analyzed by whole‐exome sequencing. Genomic profiling was correlated with tumor stages, clinical features, and survival. Our cohort included patients classified in BCLC stage 0 (9.4%), A (59.5%), B (16.2%), and C (14.9%). Among the overall 801 HCC, the most frequently mutated genes were telomerase reverse transcriptase (TERT) (58.1%), catenin beta 1 (CTNNB1) (30.7%), tumor protein 53 (TP53; 18.7%), AT‐rich interaction domain 1A (ARID1A) (13%), albumin (11.4%), apolipoprotein B (APOB) (9.4%), and AXIN1 (9.2%). Advanced‐stage HCC (BCLC B/C) showed higher frequencies of splicing factor 3b subunit 1 (SF3B1) (P = 0.0003), TP53 (P = 0.0006), and RB Transcriptional Corepressor 1 mutations (P = 0.03). G1‐G6 transcriptomic classification and the molecular prognostic 5‐gene score showed different distributions according to the stage of the disease and the type of treatment with an enrichment of G3 (P < 0.0001), poor prognostic score (P < 0.0001), and increased proliferation and dedifferentiation at the transcriptomic level in advanced HCC. The 5‐gene score predicted survival in patients treated by resection (P < 0.0001) and ablation (P = 0.01) and in advanced HCC (P = 0.04). Twenty‐two percent of advanced HCC harbored potentially druggable genetic alterations, and MET amplification was associated with complete tumor response in patients with advanced HCC treated by a specific MET inhibitor. Conclusion: Genomic analysis across the different stages of HCC revealed the mechanisms of tumor progression and helped to identify biomarkers of response to targeted therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.30811

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

Metadata

Authors
Nault, J., Martin, Y., Caruso, S., Hirsch, T. Z., Bayard, Q., Calderaro, J., Charpy, C., Copie‐Bergman, C., Ziol, M., Bioulac‐Sage, P., Couchy, G., Blanc, J., Nahon, P., Amaddeo, G., Ganne‐Carrie, N., Morcrette, G., Chiche, L., Duvoux, C., Faivre, S., Laurent, A., Imbeaud, S., Rebouissou, S., Llovet, J. M., Seror, O., Letouzé, E., & Zucman‐Rossi, J.
Venue
Hepatology
Published
2019-08-12
Volume
71
Issue
1
Pages
164-182
ISSN
  • 0270-9139 (ISSN-L)
  • 1527-3350
OpenAlex
W2949377065
Cited by
207
References
4
FWCI
15.99
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.